<DOC>
	<DOCNO>NCT03007888</DOCNO>
	<brief_summary>Primary Objective : To compare pharmacokinetics ( PK ) single multiple dos IPX203 Immediate release carbidopa-levodopa ( IR CD-LD ) subject advanced Parkinson 's disease ( PD ) . Secondary Objectives : To compare pharmacodynamics single multiple dos IPX203 IR CD-LD . To compare efficacy IPX203 IR CD-LD follow multiple dos . To evaluate safety IPX203 .</brief_summary>
	<brief_title>A Study Assess PK Pharmacodynamics IPX203 Subjects With Advanced Parkinson 's Disease</brief_title>
	<detailed_description>IPX203 investigational product contain CD‑LD . IPX203-B16-01 Study Design : A randomized , open-label , rater-blinded , multicenter , 2-treatment , 2‑period , multiple-dose crossover study . Approximately 30 qualified IR CD-LD-experienced advance PD subject randomize . The study duration approximately 8 week , include screening period .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Eligibility determine screen Visit 1 study . Diagnosed idiopathic PD age ≥ 40 year chronically treat stable regimen CDLD experience motor complication . Hoehn Yahr Stages 2 , 3 , 4 Montreal Cognitive Assessment ( MoCA ) score ≥ 24 Screening Visit `` '' state . For 4 week prior Screening , subject experience daily `` wearingoff '' episode period bradykinesia rigidity experience `` '' state upon awaken morning history . Responsive CD‑LD therapy currently treat stable regimen CD‑LD least 4 week prior Visit 1 Typically experience `` '' response first dose IR CD‑LD day ( subject history ) . By history , efficacy first morning dose IR CDLD last less 4 hour History medical condition prior surgical procedure would interfere LD absorption , gastrectomy proximal smallbowel resection . Liver enzyme value ≥ 2.5 x upper limit normal ; history severe hepatic impairment . History drug alcohol abuse within 12 month prior Screening . Received within 4 week Visit 1 plan take participation clinical study : dos controlledrelease ( CR ) LD apart single daily bedtime dose dos Rytary , additional CD ( eg , Lodosyn ) benserazide ( eg , Serazide ) , catecholOmethyl transferase inhibitor ( entacapone tolcapone ) medication contain inhibitor ( Stalevo ) . Received within 4 week Visit 1 plan take participation clinical study : nonselective monoamine oxidase ( MAO ) inhibitor , apomorphine , dopaminergic block agent include antiemetic . History psychosis within past 10 year . Treatment dopamine antagonist antipsychotic purpose psychosis bipolar disorder within last 2 year . Based clinical assessment , subject adequately comprehend terminology need complete PD Diary .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IPX203 ( carbidopa-levodopa ) Extended-Release capsule</keyword>
</DOC>